KromaTiD Hires Alex D. Vodenlich as new CEO

KromaTiD, Inc. announces that Alex D. Vodenlich of Madison, WI, will be joining as its chief executive officer and will be leading the commercialization of the company's exciting research products. Alex is a seasoned senior executive with over twenty years experience in the life science industry.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Fort Collins, CO (PRWEB) February 03, 2014

KromaTiD, Inc. announces that Alex D. Vodenlich of Madison, WI, will be joining as its chief executive officer. Mr. Vodenlich is an executive with over twenty years experience in the life science industry. He is the former President and CEO of Gentel Biosciences, Inc., a provider of multiplex immunoassay technologies.

"We chose Alex because of his successes in fundraising, sales and marketing of research reagents, and early-stage company development, all of which make him an exceptional fit for KromaTiD. He impressed us as a passionate, action-oriented leader, and someone who brings directly relevant commercialization experience to address the markets KromaTiD is seeking to serve" said Dr. Opgenorth, chairman of the company’s board of directors. “He is committed and passionate about building successful life science companies and will be a strong addition to the Colorado bioscience community."

During his tenure with Gentel, Mr. Vodenlich raised angel and other private equity funding totaling more than $15 million to develop and commercialize a proprietary protein array platform that served research and clinical laboratory markets.

“I am excited to be a part of this promising venture. The company has the right mix of protected intellectual property, product development and validation, market opportunity, management team experience, and community resources to be successful,” said Vodenlich. “Launched in the fall of 2013, KromaTiD’s dGH™ assays are already providing major research laboratories with powerful tools for understanding the roots of genetic diseases. With investor support, our goals in 2014 and beyond will be to build revenue traction and to initiate collaborations with strategic commercial partners.”

Prior to Gentel, Mr. Vodenlich served as the Vice President of Sales and Marketing for PanVera Corporation from 1993-2003, a research products company that was acquired by Life Technologies. He was one of the first 10 employees at PanVera and played a key role in developing their successful sales strategy. Prior to PanVera he was employed as a discovery research scientist with Pfizer and Abbott Laboratories, and he holds Bachelor’s and Master’s degrees from the University of Wisconsin-Madison.

KromaTiD, Inc.
KromaTiD, Inc. is a Colorado-based bioscience company dedicated to creating new products for disease research, mutation detection and chromosome analysis. KromaTiD’s patented dGH™ chromosome imaging platform provides disease researchers with the ability to detect all types of DNA rearrangements including previously undetectable classes of mutations. The company and its collaborators (including NASA, the State of Colorado Office of Economic Development and International Trade, and the Colorado Institute of Drug, Device and Diagnostic Development) expect that KromaTiD products will pave the way to identifying new diagnostic targets, developing a better understanding of the genetic causes of a variety of important human diseases, and providing more informed genetic counseling. KromaTiD develops and markets dGH technology under license from Colorado State University. For more information on products and services offered by KromaTiD, visit http://www.kromatid.com.


Contact

  • Paul Spieker
    pspieker@fstcapital.com
    +1 (303) 919-8010
    Email